Mucosal vaccination promotes clearance of Streptococcus agalactiae vaginal colonization

被引:31
作者
Baker, Jacqueline A. [1 ]
Lewis, Emma L. [1 ]
Byland, Leah M. [1 ]
Bonakdar, Maryam [2 ]
Randis, Tara M. [1 ,2 ]
Ratner, Adam J. [2 ,3 ]
机构
[1] Columbia Univ, Dept Pediat, New York, NY 10027 USA
[2] NYU, Sch Med, Dept Pediat, New York, NY USA
[3] NYU, Sch Med, Dept Microbiol, New York, NY 10016 USA
基金
美国国家卫生研究院;
关键词
Group B Streptococcus; Vaccine; Colonization; GROUP-B STREPTOCOCCUS; FEMALE GENITAL-TRACT; INTRANASAL IMMUNIZATION; ANTIBODY-RESPONSES; MATERNAL ANTIBODY; IMMUNE-RESPONSES; IGG TRANSPORT; POLYSACCHARIDE; SUBUNIT; PROTECTION;
D O I
10.1016/j.vaccine.2017.01.029
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Group B Streptococcus (GBS) is a leading cause of morbidity and mortality in infants, and colonization of the maternal genital tract is the primary risk factor for newborn infection. Despite the importance of mucosal colonization in GBS pathogenesis, relevant host and bacterial factors are incompletely understood. We investigated the role of humoral immunity in clearance of vaginal colonization in vivo. B-cell-deficient mice or those lacking neonatal Fc-receptor, a mediator of IgG transport to the vaginal mucosa, exhibit prolonged GBS vaginal colonization compared to wild type animals. Intranasal but not intramuscular immunization induced systemic and mucosal immune responses and decreased GBS colonization duration without altering initial colonization density. Vaccine-induced clearance of GBS was serotype-specific, suggesting a role for anti-capsule antibodies in protection. Our results support a role for humoral immunity in GBS eradication from the female genital tract and suggest that mucosal vaccination may prime colonization clearance. (C) 2017 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
引用
收藏
页码:1273 / 1280
页数:8
相关论文
共 51 条
[1]  
[Anonymous], 2010, MMWR-MORBID MORTAL W
[2]   Maternal Antibody at Delivery Protects Neonates From Early Onset Group B Streptococcal Disease [J].
Baker, Carol J. ;
Carey, Vincent J. ;
Rench, Marcia A. ;
Edwards, Morven S. ;
Hillier, Sharon L. ;
Kasper, Dennis L. ;
Platt, Richard .
JOURNAL OF INFECTIOUS DISEASES, 2014, 209 (05) :781-788
[3]   IMMUNIZATION OF PREGNANT-WOMEN WITH A POLYSACCHARIDE VACCINE OF GROUP-B STREPTOCOCCUS [J].
BAKER, CJ ;
RENCH, MA ;
EDWARDS, MS ;
CARPENTER, RJ ;
HAYS, BM ;
KASPER, DL .
NEW ENGLAND JOURNAL OF MEDICINE, 1988, 319 (18) :1180-1185
[4]   Safety and immunogenicity of capsular polysaccharide-tetanus toxoid conjugate vaccines for group B streptococcal types Ia and Ib [J].
Baker, CJ ;
Paoletti, LC ;
Wessels, MR ;
Guttormsen, HK ;
Rench, MA ;
Hickman, ME ;
Kasper, DL .
JOURNAL OF INFECTIOUS DISEASES, 1999, 179 (01) :142-150
[5]   CORRELATION OF MATERNAL ANTIBODY DEFICIENCY WITH SUSCEPTIBILITY TO NEONATAL GROUP-B STREPTOCOCCAL INFECTION [J].
BAKER, CJ ;
KASPER, DL .
NEW ENGLAND JOURNAL OF MEDICINE, 1976, 294 (14) :753-756
[6]   Use of capsular polysaccharide-tetanus toxoid conjugate vaccine for type II group B Streptococcus in healthy women [J].
Baker, CJ ;
Paoletti, LC ;
Rench, MA ;
Guttormsen, HK ;
Carey, VJ ;
Hickman, ME ;
Kasper, DL .
JOURNAL OF INFECTIOUS DISEASES, 2000, 182 (04) :1129-1138
[7]   IMMUNOGENICITY OF POLYSACCHARIDES FROM TYPE-III, GROUP-B STREPTOCOCCUS [J].
BAKER, CJ ;
EDWARDS, MS ;
KASPER, DL .
JOURNAL OF CLINICAL INVESTIGATION, 1978, 61 (04) :1107-1110
[8]  
BAKER CJ, 1985, REV INFECT DIS, V7, P458
[9]   Intranasal vaccination of humans with recombinant cholera toxin B subunit induces systemic and local antibody responses in the upper respiratory tract and the vagina [J].
Bergquist, C ;
Johansson, EL ;
Lagergard, T ;
Holmgren, J ;
Rudin, A .
INFECTION AND IMMUNITY, 1997, 65 (07) :2676-2684
[10]   Identification of group B streptococcal Sip protein, which elicits cross-protective immunity [J].
Brodeur, BR ;
Boyer, M ;
Charlebois, I ;
Hamel, J ;
Couture, F ;
Rioux, CR ;
Martin, D .
INFECTION AND IMMUNITY, 2000, 68 (10) :5610-5618